SelectQuote Shrinks Its Way Toward an Inflection It Has Promised Before
Revenue down 15%, a deliberately smaller agent force, and a $60M cash target — plus a reverse split management buried in the middle of the call
SLQT · Earnings Call · 2026-11-04
An $88 Million Company Making a $124 Million Argument
SelectQuote entered its fiscal Q1 2027 print as a sub-$100 million market cap with a full-history return of roughly -98% and a 90-day slide of more than 40%. It left the print up about 36% in four sessions — and still some 45% below its July 1 high of $0.89. That shape is the whole story in miniature: the equity is a call option on management's cash-flow arithmetic, and the arithmetic is improving faster than the revenue. Which is the first genuinely new thing. Fiscal Q1 revenue fell 15% to $280M, yet adjusted EBITDA loss of $17M improved by more than $15M year over year, and trailing-twelve-month adjusted EBITDA reached $124M, up 30%. “On a trailing 12-month basis, our adjusted EBITDA totaled $124 million, representing a 30% increase from the prior trailing 12-month period.” — Tim Danker, Chief Executive Officer · 2026-11-04 The company reiterated at least $60M of fiscal 2027 operating cash flow. Against an enterprise carrying effective net cash of negative $357M, that is the number that matters. Notably, none of this is happening in a hot sector tape. This quarter's market-wide keyword leaderboard is a rates-and-banks board — IRB models, Fed rate hikes, core deposits. There is no Medicare Advantage theme anywhere near the market's top keywords. SelectQuote's drama is entirely idiosyncratic; the nearest adjacent reporter in the last five days is a health-services conglomerate talking about margin improvement off a trough. That isolation cuts both ways: no sector tailwind, but also no sector crowding.The Deliberate Shrink
The most prominent new language in this quarter's keyword set is a retreat dressed as discipline: smaller agent force leapt to the top of the company's theme list, alongside plan terminations, policyholder retention, and agent capacity. For four straight years, "agent force" was growth vocabulary at this company — tenured agents, agent productivity, agent throughput, hiring ahead of AEP. Now the CEO volunteers that the headcount cut is a choice, not a symptom: “Our deliberate decision to operate with a smaller agent force in senior drove approximately 15% of the year-over-year decline.” — Ryan Clement, Unknown · 2026-11-04 That is the honest read of the quarter. Senior revenue of $51M fell $8M, but the segment's EBITDA loss improved $9M, and the tenured agent base is flat year over year — the company kept its best producers and simply stopped buying volume it does not expect to be paid for. Life insurance quietly delivered the cleanest proof, with adjusted EBITDA up 31% to $7M on a 17% margin, more than 500 basis points better, helped by lead transfers from Senior at no incremental acquisition cost. On the front end of AEP, the tone is noticeably better than the numbers would license. President Bob Grant on carrier commissions: “I do think as far as the commissions go, this so far has been a much more stable environment.” — Bob Grant, President · 2026-11-04 And Tim Danker on recapture: “we are leading in terms of recapture rate of 30% last year. We are going to try to better that, which has a very positive cash flow impact.” — Tim Danker, Chief Executive Officer · 2026-11-04 Recapturing a terminated policyholder means booking a new policy on an existing relationship — the cheapest commission dollar this business can earn.The Inflection That Keeps Receding
Here is where the narrative and the transcript history rub against each other. Danker told this call that “we believe we are nearing an inflection point for the Medicare Advantage industry.” — Tim Danker, Chief Executive Officer · 2026-11-04 Investors should know that inflection point is a recurring character at SelectQuote, not a fresh arrival. In August 2026, the language was: “it feels like, carrier-dependent, they're getting towards hopefully the later innings of this recovery and a reemergence to what we would call responsible or targeted growth in plan year 2028.” — Timothy Danker, Chief Executive Officer · 2026-08-25 In February 2026, it was already “some potential reemergence to targeted growth for plan year 2028.” — Timothy Danker, Chief Executive Officer (CEO) · 2026-05-05 The target keeps being plan year 2028 — and we are now in the selling season for plan year 2027. That does not make the claim wrong; carriers' medical loss ratios are genuinely better. But "nearing an inflection" has been the standing posture for at least three quarters, and the policy-volume guidance is still down year over year. The one place management declined to lean into bullishness was the question that mattered most. Asked whether lifetime value growth of 16% reflected carrier repricing, mix, or a structural change in how SelectQuote sells, the CFO answered: “LTVs tend to move with carrier mix... there has been a benefit from CMS commission rate increases.” — Ryan Clement, Unknown · 2026-11-04 That is an administrative tailwind and a mix effect, not a moat — and the analyst's question about durability went unanswered.Olathe, and the 20% That Isn't There Yet
Underneath the Medicare cyclicality sits the most genuinely company-unique asset: a pharmacy business with a custom Pharmacy Management System and a purpose-built Kansas facility management says runs about 30% more efficient than legacy sites. Healthcare Services revenue fell 16% to $186M on Inflation Reduction Act drug pricing, yet segment adjusted EBITDA rose 56% to $11M and EBITDA per member jumped over 60% to $108. Management still expects to double segment margins this year — a promise made on the prior call and repeated here. The catch is penetration. “Today, fewer than 20% of our prescriptions are shipped from our hyper-efficient Kansas facility.” — Tim Danker, Chief Executive Officer · 2026-11-04 The remaining 80% is the upside and the risk in the same sentence; retrofitting legacy pharmacies is described as a slower, more complicated transfer than simply routing new members. Meanwhile the AI numbers are real and small: more than 200,000 calls screened in Q1, saving over 600,000 minutes of agent talk time, with voice AI now handling formal enrollment after a licensed agent completes needs analysis. That is a labor-efficiency story, not a growth story — and it is precisely why the last filed quarter's operating margin of 10.2% matters more than any revenue line here.What Management Buried
Midway through the CFO's prepared remarks came the item with the largest implications for equity holders, delivered as an aside: SelectQuote will seek shareholder approval on November 10 for a reverse stock split later in the month, to remain listed on the NYSE, with the assurance that “it has no material impact on economic interests, and we are not raising capital.” — Ryan Clement, Unknown · 2026-11-04 That theme, too, has history — in May 2026 management was already promising to “ensure that this company will be listed on the New York Stock Exchange.” — Timothy Danker, Chief Executive Officer (CEO) · 2026-05-05 It is now being executed.The preferred dividend has been accruing in kind; converting it to cash is the cleanest available proof that the cash engine is real. With liabilities at 50.3% of assets, down roughly 24 points from the 2024 peak, and receivables at 54% of revenue, the deleveraging path is no longer speculative. What changed this quarter, in one line: SelectQuote shrank on purpose and made more money per unit of shrinkage, while the inflection it keeps forecasting stayed one plan year away. The market gave it 36% in four days for the shrinkage. It has not yet paid for the inflection.While we're not specifically guiding to fiscal 2028, we do see on the horizon a path to cash paying the dividend, and that would be our plan.